Upcoming Webcast to Share Exciting New Data from Caribou Biosciences
Caribou Biosciences, Inc. (NASDAQ: CRBU), a pioneering clinical-stage biopharmaceutical company known for its advanced CRISPR genome-editing technology, is set to host a webcast where it will unveil new and significant updates from two of its innovative allogeneic CAR-T cell therapy programs. The event will take place soon, and is expected to shed light on the results from its ANTLER phase 1 clinical trial.
Overview of the Webcast Features
During the webcast, which is scheduled to start at 8:00 am ET, Caribou will present findings from trials related to vispacabtagene regedleucel, more commonly referred to as vispa-cel. This therapy targets relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL) and is noteworthy for being the first allogeneic CAR-T therapy to utilize a PD-1 knockout strategy. By limiting premature exhaustion of CAR-T cells, vispa-cel shows promise in enhancing treatment efficacy.
In addition, the webcast will introduce the first clinical data from its CaMMouflage Phase 1 clinical trial, which focuses on CB-011, an allogeneic anti-BCMA CAR-T cell therapy aimed at treating relapsed or refractory multiple myeloma (r/r MM). As a company focused on groundbreaking solutions, Caribou aims to provide insights into its potential pivotal phase 3 trial design for vispa-cel and outline next steps for the ongoing development of CB-011.
What Is vispacabtagene regedleucel?
Vispacabtagene regedleucel, previously known as CB-010, stands out as a front-runner in the allogeneic CAR-T cell therapy landscape. Its distinct genome-editing features include a PD-1 knockout, positioning it to create CAR-T cells that can deliver better treatment outcomes while combating certain resistance factors associated with other therapies. The FDA has recognized vispa-cel’s potential by granting it several designations, including Regenerative Medicine Advanced Therapy (RMAT), Orphan Drug, and Fast Track status.
Introduction of CB-011
Similarly, CB-011 presents innovative approaches in tackling multiple myeloma. This therapy is engineered with unique mechanisms, including an immune cloaking strategy involving a B2M knockout and the insertion of a B2M–HLA-E fusion protein. Such engineering is designed to reduce immune-mediated rejection, which can often hinder the efficacy of CAR-T therapies. The FDA has accorded CB-011 with Fast Track and Orphan Drug designations, emphasizing its potential impact in the therapeutic space for hematologic malignancies.
About Caribou Biosciences, Inc.
Caribou Biosciences is dedicated to leveraging the capabilities of its CRISPR genome-editing platform, including technologies that allow for superior precision in developing cell therapies. With an aim to offer transformative therapies for various devastating diseases, Caribou is concentrating on its CAR-T cell therapies, vispacabtagene regedleucel and CB-011, which are orchestrated for the rapid treatment of patients.
For those interested in attending, a live webcast can be accessed on the official Caribou website, under the Events page. Attendees will also have the opportunity to view the archived presentation for 30 days following the event.
Contact Information
For further inquiries, please reach out to Peggy Vorwald, PhD, at investor.relations@cariboubio.com or media@cariboubio.com.
Frequently Asked Questions
What is the purpose of the Caribou Biosciences webcast?
The webcast aims to share new data updates from Caribou's CAR-T cell therapy programs targeting lymphoma and multiple myeloma.
When is the Caribou Biosciences webcast scheduled?
The webcast will take place at 8:00 am ET on the specified date.
What are vispacabtagene regedleucel and CB-011?
Vispacabtagene regedleucel is an allogeneic CAR-T therapy for B cell non-Hodgkin lymphoma, while CB-011 is designed for multiple myeloma treatment.
How does vispacabtagene regedleucel enhance CAR-T cell activity?
It utilizes a PD-1 knockout strategy to limit premature exhaustion of CAR-T cells, potentially improving treatment efficacy.
How can I access the webcast?
The webcast will be accessible through Caribou's official website on the Events page.
